ÂÜÀòÂÒÂ×

Dr. Dukes joined the Iovance Board of Directors and was appointed Chairman of the Board in August 2016. Dr. Dukes is a Venture Partner at OrbiMed Advisors. He previously served as Senior Vice President and Head of Business Development and Licensing for Merck Research Laboratories. Prior to joining Merck, Dr. Dukes was Vice President of External Research & Development at Amgen. Dr. Dukes has also served as President and Chief Executive Officer, and a member of the Board of Directors, of Essentialis Therapeutics, a clinical stage biotechnology company focused on the development of breakthrough medicines for the treatment of rare metabolic diseases. Previously, Dr. Dukes was Vice President of Scientific and Technology Licensing at GlaxoSmithKline, and prior to that, he held various positions at Glaxo Wellcome, including Head of Exploratory Development for Metabolic and Urogenital Diseases and Head of Ion Channel Drug Discovery Group. Dr. Dukes serves on the Board of Directors of Themis Biosciences, Ikena Oncology, KaNDy Therapeutics (previously as Chairman), NeRRe Therapeutics, ReViral Limited, and ENYO Therapeutics. Dr. Dukes co-founded and is Chief Executive Officer of Theseus Pharmaceuticals, co-founded and serves on the Board of Directors of Kartos Therapeutics, and co-founded Telios Pharma where he serves as President. Dr. Dukes holds an M.J. and Ph.D. from the University of Oxford, an M.S. in Cardiovascular Studies from the University of Leeds and a B.S. in Pharmacology from the University of Bath.